Related Experiment Video
Updated: Jan 14, 2026
05:06
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
2.3K
Opportunities and obstacles associated with the Medicare Diabetes Prevention Program
Melanie T Turk1, Natalie D Ritchie, Bailey Norton
1Duquesne University School of Nursing, 518 Fisher Hall, 600 Forbes Ave, Pittsburgh, PA 15282.
The American Journal of Managed Care
|October 27, 2025
Summary
The Medicare Diabetes Prevention Program (MDPP) faces implementation challenges despite full coverage. Supportive cultures and staff are key opportunities, while Medicare designation, reimbursement, and regulations pose obstacles for this vital diabetes prevention initiative.
Area of Science:
- Public Health
- Health Services Research
- Diabetes Prevention
Background:
- Medicare Diabetes Prevention Program (MDPP) offers full coverage for type 2 diabetes prevention.
- Limited program suppliers and participant enrollment hinder MDPP's public health impact.
- Understanding implementation facilitators and barriers is crucial for expanding the program.
Purpose of the Study:
- To explore opportunities and obstacles in MDPP implementation.
- To gather insights from the perspective of program coordinators nationwide.
- To identify strategies for improving MDPP delivery and uptake.
Main Methods:
- Qualitative study design.
- Individual interviews conducted with 12 program coordinators from MDPP suppliers.
- Data analyzed using the Rapid Group Analysis Process.
Main Results:
- Two opportunity themes: supportive organizational cultures and committed staff.
- Four obstacle themes: Medicare designation challenges, claims and reimbursement logistics, inadequate payment models (pay-for-performance, Medicare Advantage), and complex government requirements.
- Recommendations include peer mentors and a fee-for-service model.
Conclusions:
- Organizational culture is a strength for MDPP implementation.
- Policy changes are needed to address identified obstacles.
- Wider dissemination of MDPP is essential to prevent type 2 diabetes in eligible Medicare beneficiaries.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:21Drug Dosing: Obese Patients
217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K